EGFR and non-small cell lung carcinoma: However, it is important to point out that using the actual available therapies (surgical debulking, chemo-radiotherapy) the prognosis of the different NSCLC subgroups subdivided according to the presence of BRAF, EGFR, KRAS or PI3KCA mutations or FGFR1 amplifications or ALK-EML4 fusions is not prognostically relevant [87].